Valuation: Structure Therapeutics Inc.

Market Cap 1.45B 1.3B 1.19B 1.08B 2.05B 136B 2.1B 14.26B 5.68B 72.82B 5.45B 5.33B 229B P/E 2026 *
-12.6x
P/E 2027 * -9.31x
Enterprise Value 484M 432M 398M 361M 684M 45.37B 701M 4.76B 1.9B 24.29B 1.82B 1.78B 76.5B EV / Sales 2026 *
11.6x
EV / Sales 2027 * 19,625x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day+5.21%
1 week+4.59%
Current month-2.10%
1 month-16.17%
3 months-60.21%
6 months-44.13%
Current year-69.22%
1 week 18.7
Extreme 18.7
22.13
1 month 18.7
Extreme 18.7
25.5
Current year 18.7
Extreme 18.7
94.77
1 year 18.7
Extreme 18.7
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Conversion

Chief Technology Officer

-20,040 0.0143%
1/9/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/8/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
+5.21%+4.59%-36.84%-62.22% 1.45B
+2.24%+5.83%+58.47%+65.65% 66.7B
+4.66%+5.77%+16.93%+82.87% 56.88B
-0.60%+2.36%+24.32%+97.19% 56.53B
+2.55%+15.52%+26.77%+120.17% 46.49B
+2.58%+7.89%+30.88%+45.30% 44.8B
+4.09%+6.37%+219.07%+899.75% 41.59B
-0.47%+9.60%+27.53%+52.88% 35.35B
+3.80%-6.42%+98.16%+68.09% 33.29B
+1.48%+6.21%-39.51%+395.73% 25.1B
Average +2.60%+2.26%+42.58%+176.54% 40.82B
Weighted average by Cap. +2.37%+3.93%+51.87%+180.31%

Financials

2026 *2027 *
Net sales 41.67M 37.19M 34.22M 31.06M 58.86M 3.91B 60.33M 409M 163M 2.09B 156M 153M 6.59B 45.45K 40.57K 37.33K 33.88K 64.21K 4.26M 65.8K 447K 178K 2.28M 171K 167K 7.18M
Net income -314M -280M -258M -234M -443M -29.41B -454M -3.08B -1.23B -15.75B -1.18B -1.15B -49.6B -471M -420M -387M -351M -665M -44.15B -682M -4.63B -1.84B -23.64B -1.77B -1.73B -74.45B
Net Debt -967M -863M -794M -721M -1.37B -90.65B -1.4B -9.5B -3.79B -48.53B -3.63B -3.55B -153B -559M -499M -459M -417M -790M -52.42B -810M -5.49B -2.19B -28.06B -2.1B -2.05B -88.38B
Projected Income Statement - Annual - Structure Therapeutics Inc.
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
10/11/26 USD 21.41 +5.21% 1,234,965
06/11/26 USD 20.35 +6.66% 1,621,152
05/11/26 USD 19.08 -6.29% 1,012,046
04/11/26 USD 20.36 +0.05% 738,527
03/11/26 USD 20.35 -0.59% 612,885
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Structure Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
20.35USD
Average target price
107.29USD
Spread / Average Target
+427.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Structure Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. GPCR Stock